Quick Answer
Niacinamide Skin Hydration Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Its pathophysiology involves a deficiency in essential stratum corneum lipids such as ceramides, cholesterol, and free fatty acids, together with reduced levels of natural moisturizing factors (NMFs) and increased TEWL [,].
Key Takeaways
- 01Its pathophysiology involves a deficiency in essential stratum corneum lipids such as ceramides, cholesterol, and free fatty acids, together with reduced levels of natural moisturizing factors (NMFs) and increased TEWL [,]. [Morgado‐Carrasco Daniel (2026)]
- 02While conventional management typically relies on basic emollients and cutaneous hydration [,], there is a growing need for multi‐active formulations that facilitate functional barrier enhancement and address associated symptoms such as pruritus. [Morgado‐Carrasco Daniel (2026)]
- 03On the treated leg, baseline values (33.8 ± 0.8 μS; 95% CI: 32.2–35.4) increased by 16.9% (39.5 ± 0.9 μS; 95% CI: 37.7–41.3) at T7 and 21.6% (41.1 ± 0.8 μS; 95% CI: 39.5–42.7) at T28, both statistically significant in comparison to baseline and to the untreated control ( < 0.05). [Morgado‐Carrasco Daniel (2026)]
- 04The stratum corneum (SC) exhibits a distinctive “bricks and mortar” structure, with protein‐rich corneocytes embedded within a matrix of intercellular lipids [,,]. [Morgado‐Carrasco Daniel (2026)]
The current Migaku evidence database contains 1 reusable source document for Niacinamide Skin Hydration Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts.
- Its pathophysiology involves a deficiency in essential stratum corneum lipids such as ceramides, cholesterol, and free fatty acids, together with reduced levels of natural moisturizing factors (NMFs) and increased TEWL [,]. [Morgado‐Carrasco Daniel (2026); evidence level 2]
- While conventional management typically relies on basic emollients and cutaneous hydration [,], there is a growing need for multi‐active formulations that facilitate functional barrier enhancement and address associated symptoms such as pruritus. [Morgado‐Carrasco Daniel (2026); evidence level 2]
- On the treated leg, baseline values (33.8 ± 0.8 μS; 95% CI: 32.2–35.4) increased by 16.9% (39.5 ± 0.9 μS; 95% CI: 37.7–41.3) at T7 and 21.6% (41.1 ± 0.8 μS; 95% CI: 39.5–42.7) at T28, both statistically significant in comparison to baseline and to the untreated control ( < 0.05). [Morgado‐Carrasco Daniel (2026); evidence level 2]
- The stratum corneum (SC) exhibits a distinctive “bricks and mortar” structure, with protein‐rich corneocytes embedded within a matrix of intercellular lipids [,,]. [Morgado‐Carrasco Daniel (2026); evidence level 2]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources